Lakewood-Amedex Biotherapeutics Inc. LABT
—
1.67
(0.16)
(8.74%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow LABT
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+2 more TTM periods Free account |
— | — | — | 0.00% | |
| — | — | 0.00% | (302.50%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
— | 0.00% | 0.00% | (177.63%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (4.59) | (3.46) | |
Free Cash Flow |
— | (8.58) | (3.21) | (4.91) | |
Piotroski F-Score |
— | — | — | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 496.53% | 113.34% | (55.04%) | |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 0.00% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
— | 0.00 | 0.00 | 0.65 | |
Depreciation/Fixed assets |
— | 25.18 | 25.94 | 30.59 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | (4.59) | (3.46) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
— | — | — | 0.00% |
Columns are period end dates